They found that the expression strength of E-cadherin in low-grade astrocytomas (grade I–II) was higher than that presented in high-grade astrocytomas (grade III–IV) (P<0.0001), while the expression strength of E-cadherin in non-CNS tumors is higher than that found in grade I astrocytomas. The gene discussed is CDH1; the disease is central nervous system neoplasm.